Accueil   Diary - News   All news Valbiotis succeeds in the industrial production of VALEDIA, in collaboration with the Pierre Fabre group

Valbiotis succeeds in the industrial production of VALEDIA, in collaboration with the Pierre Fabre group

VALBIOTIS succeeds in the industrial production of VALEDIA®, a major scientific innovation for prediabetic people, in collaboration with the Pierre Fabre group

 

  • Confirmation of VALBIOTIS’s capacity to produce VALEDIA® in compliance with North American and European industrial standards.
  • A key stage in the health claim application for the two leading markets worldwide, North America and Europe.
  • An accomplishment due to the combined expertise of VALBIOTIS and the Pierre Fabre Group, which specializes in the industrial manufacture of plant-based products.

 

La Rochelle, 28 May 2019 (5:40 CEST) – VALBIOTIS FR0013254851 – ALVAL / PEA/SME eligible), a French Research & Development company committed to scientific innovation for preventing and combating metabolic diseases, announces the successful industrial production of VALEDIA® (active substance TOTUM-63), the most advanced product in the VALBIOTIS portfolio. This achievement is the result of a collaboration with the Pierre Fabre group, a world-renowned expert in the industrial production of plant-based
active substances.

 

Read the press release

By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to dpo@lyonbiopole.com. More details are available by clicking here I agree